Patents by Inventor Ulrich Emde

Ulrich Emde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120220587
    Abstract: Compounds of the formula (I), in which X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, R10 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours.
    Type: Application
    Filed: September 6, 2010
    Publication date: August 30, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Ulrich Emde, Hans Peter Buchstaller, Markus Klein, Christina Esdar, Joerg Bomke
  • Publication number: 20120208808
    Abstract: Compounds of the formula (I), in which X, R1 and R2 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours.
    Type: Application
    Filed: September 24, 2010
    Publication date: August 16, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Hans Peter Buchstaller, Ulrich Emde, Markus Klein, Christina Esdar, Joerg Bomke
  • Patent number: 8236824
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, Alk and D have the meanings indicated in claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: August 7, 2012
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Lars Thore Burgdorf, Norbert Beier, Johannes Gleitz, Ulrich Emde, Christine Charon, Denis Carniato
  • Patent number: 8207345
    Abstract: Compounds of the formula (I), in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: June 26, 2012
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Frank Zenke
  • Patent number: 8198452
    Abstract: The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I wherein R1, R2, R3, R6, R7 and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer.
    Type: Grant
    Filed: May 26, 2007
    Date of Patent: June 12, 2012
    Assignee: Merck Patent Gesellschaft MIT Beschränkter Haftung
    Inventors: Kai Schiemann, Ulrich Emde, Tobias Schlueter, Christoph Saal, Michael Maiwald
  • Publication number: 20120130147
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 24, 2012
    Inventors: Dirk FINSINGER, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Patent number: 7915416
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: March 29, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Dirk Finsinger, Wolfgang Staehle, Christiane Amendt, Ulrich Emde, Frank Zenke
  • Patent number: 7893082
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: February 22, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Nina Heiss, Frank Zenke
  • Patent number: 7875614
    Abstract: Compounds of the formula I, in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3 and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: January 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Kai Schiemann, Ulrich Emde, Frank Zenke, Christiane Amendt
  • Publication number: 20110009455
    Abstract: The present invention relates to novel compounds of general formula (I) and uses thereof. The present invention relates to novel compounds of general formula (I) for use as glucokinase activators in the treatment of diabetes and obesity.
    Type: Application
    Filed: February 5, 2009
    Publication date: January 13, 2011
    Applicant: Merck Patent Gesellschaft
    Inventors: Christoph Saal, Lars Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • Patent number: 7868172
    Abstract: Compounds of the formula I, in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: January 11, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Ulrich Emde, Dirk Finsinger, Johannes Gleitz, Helmut Reubold, Frank Zenke
  • Publication number: 20100331338
    Abstract: Novel compounds of the Formula (I) in which R1, R2, R3, and R4 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Type 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: February 2, 2009
    Publication date: December 30, 2010
    Applicant: Merck Patent GMBH
    Inventors: Lars Burgdorf, Ulrich Emde, Johannes Gleitz, Norbert Beier, Christine Charon
  • Publication number: 20100331346
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R2?, R2?, R3, R4, R5, R6, R7 and R8 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: December 23, 2008
    Publication date: December 30, 2010
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Stefan Bender, Lars Thore Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • Publication number: 20100311976
    Abstract: The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presence of a protonic acid or Lewis acid with a suitable solvent. A, B, C have the meaning as described in the specification.
    Type: Application
    Filed: November 20, 2008
    Publication date: December 9, 2010
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Ulrich Emde, Oliver Block, Kai Schiemann
  • Publication number: 20100210690
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, Alk and D have the meanings indicated in claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: September 9, 2008
    Publication date: August 19, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Lars Thore Burgdorf, Norbert Beier, Johannes Gleitz, Ulrich Emde, Christine Charon, Denis Carniato
  • Publication number: 20090176820
    Abstract: The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I wherein R1, R2, R3, R6, R7 and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer.
    Type: Application
    Filed: May 26, 2007
    Publication date: July 9, 2009
    Inventors: Kai Schiemann, Ulrich Emde, Tobias Schlueter, Christoph Saal, Michael Maiwald
  • Publication number: 20090118267
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: February 13, 2006
    Publication date: May 7, 2009
    Inventors: Dirk Finsinger, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Publication number: 20090030028
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Application
    Filed: June 3, 2005
    Publication date: January 29, 2009
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Dirk Finsinger, Wolfgang Staehle, Christiane Amendt, Ulrich Emde, Frank Zenke
  • Publication number: 20080312244
    Abstract: Compounds of the formula I, in which R, X, R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are inhibitors of CHK1 CHK2 and SGK kinases and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: June 30, 2006
    Publication date: December 18, 2008
    Inventors: Werner Mederski, Ulrich Emde, Gerhard Barnickel, Frank Zenke, Hartmut Greiner, Frank Stieber
  • Publication number: 20080234299
    Abstract: Compounds of the formula (I), in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3, k and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 17, 2006
    Publication date: September 25, 2008
    Applicant: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Kai Schiemann, Ulrich Emde